Skip to content
stoqly

Community Health Systems Inc

CYH NYSE Services-General Medical & Surgical Hospitals, Nec Financials FY2016–FY2025

Revenue Total sales reported in the income statement.
$12.5B
1.2% vs prior year
Operating margin Operating income as a share of revenue.
11.9%
7.6 pts
Net income Profit after all expenses, interest and tax.
$509M
Free cash flow Cash from operations minus capital spending.
$208M
73.3%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
15.9%
11.4 pts
Market cap Last close times the latest diluted share count, so it is approximate.
β€”
P/E Last close divided by diluted earnings per share over the last four quarters.
β€”
On $1.86 EPS (TTM)

What Community Health Systems Inc does

No business description yet.

Legal name
COMMUNITY HEALTH SYSTEMS INC
Fiscal year ends
December 31, 2025
Latest annual report
10-K Β· Feb 19, 2026
Accession Β· CIK
0001193125-26-059509
0001108109

Revenue and margins

Community Health Systems Inc had $12.5B of revenue in fiscal 2025, down 1.2% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was $208M in fiscal 2025, 1.7% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Community Health Systems Inc returned β€” to shareholders in fiscal 2025. The diluted share count rose 2.2%.

Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Community Health Systems Inc can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $507M$118M$38.0M$37.0M$260M
Debt incl. finance leases $12.4B$11.9B$11.7B$11.6B$10.6B
Net debt / EBITDA 6.1x8.7x8.0x11.3x5.4x
Current ratio 1.5x1.4x1.5x1.4x1.5x
Quick ratio 1.5x1.4x1.5x1.4x1.5x
Total assets $15.2B$14.7B$14.5B$14.1B$13.2B
Total liabilities $16.0B$15.4B$15.3B$15.4B$14.0B
Shareholders' equity βˆ’$1.4Bβˆ’$1.4Bβˆ’$1.4Bβˆ’$1.9Bβˆ’$1.4B
Net debt (βˆ’ = net cash) $11.9B$11.7B$11.7B$11.6B$10.3B

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

β€”

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive βœ• βœ• βœ• βœ• βœ“ βœ“ βœ“ βœ• βœ• βœ“
Cash from operations is positive βœ“ βœ“ βœ“ βœ“ βœ“ βœ• βœ“ βœ“ βœ“ βœ“
Return on assets rose β€” βœ• βœ“ βœ“ βœ“ βœ• βœ• βœ• βœ• βœ“
Cash from operations exceeds net income βœ“ βœ“ βœ“ βœ“ βœ“ βœ• βœ“ βœ“ βœ“ βœ“
Debt fell relative to assets β€” βœ• βœ• βœ• βœ“ βœ• βœ“ βœ• βœ• βœ“
Current ratio rose β€” βœ“ βœ• βœ“ βœ“ βœ• βœ• βœ“ βœ• βœ“
Share count didn't rise β€” βœ• βœ• βœ• βœ• βœ• βœ“ βœ• βœ• βœ•
Gross margin rose β€” βœ• βœ“ βœ“ βœ• βœ“ βœ“ βœ“ βœ“ βœ“
Revenue rose relative to assets β€” βœ“ βœ“ βœ• βœ• βœ“ βœ“ βœ“ βœ“ βœ“
F-score β€” / 34 / 95 / 95 / 96 / 93 / 97 / 95 / 94 / 98 / 9
Accruals ratio βˆ’13.0%βˆ’16.4%βˆ’6.4%βˆ’6.7%βˆ’10.5%2.3%βˆ’1.7%βˆ’2.4%βˆ’7.0%βˆ’0.2%
Altman Z'' 0.31βˆ’0.64βˆ’0.26βˆ’0.250.310.27βˆ’0.080.03βˆ’0.370.28

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $18.4B $15.4B $14.2B $13.2B $11.8B $12.4B $12.2B $12.5B $12.6B $12.5B
Gross profit $15.4B $12.7B $11.8B $11.1B $9.8B $10.3B $10.2B $10.5B $10.7B $10.6B
Operating income βˆ’$860M βˆ’$1.9B $208M $650M $1.1B $1.4B $821M $957M $542M $1.5B
Pretax income βˆ’$1.7B βˆ’$2.8B βˆ’$715M βˆ’$430M $422M $499M $349M $207M βˆ’$283M $724M
Income tax βˆ’$104M βˆ’$449M βˆ’$11.0M $160M βˆ’$185M $131M $170M $191M $79.0M $48.0M
Net income βˆ’$1.7B βˆ’$2.5B βˆ’$788M βˆ’$675M $511M $230M $46.0M βˆ’$133M βˆ’$516M $509M
Diluted EPS βˆ’$15.54 βˆ’$22.00 βˆ’$6.99 βˆ’$5.93 $4.39 $1.76 $0.35 βˆ’$1.02 βˆ’$3.90 $3.77
Diluted shares 0.11B 0.11B 0.11B 0.11B 0.12B 0.13B 0.13B 0.13B 0.13B 0.14B
Cash flow
Cash from operations $1.1B $773M $274M $385M $2.2B βˆ’$131M $300M $210M $480M $543M
Capital expenditure $744M $564M $527M $438M $440M $469M $415M $467M $360M $335M
Free cash flow $393M $209M βˆ’$253M βˆ’$53.0M $1.7B βˆ’$600M βˆ’$115M βˆ’$257M $120M $208M
Depreciation and amortization $1.1B $861M $700M $608M $558M $540M $534M $505M $486M $426M
Stock-based compensation $46.0M $24.0M $13.0M $10.0M $13.0M $25.0M $20.0M $22.0M $17.0M $11.0M
Acquisitions $123M $6.0M $26.0M $13.0M $1.0M $3.0M $9.0M $38.0M $25.0M $1.0M
Balance sheet
Cash and short-term investments $238M $563M $196M $216M $1.7B $507M $118M $38.0M $37.0M $260M
Total debt $15.2B $13.9B $13.6B $13.4B $12.2B $12.1B $11.6B $11.5B $11.5B $10.4B
Finance lease liabilities β€” β€” β€” $113M $79.0M $241M $223M $216M $195M $203M
Current assets $4.7B $4.1B $3.5B $3.4B $4.5B $3.5B $3.1B $3.2B $3.3B $3.2B
Current liabilities $2.9B $2.4B $2.4B $2.3B $2.8B $2.4B $2.2B $2.1B $2.3B $2.2B
Property and equipment, net $8.1B $7.1B $6.1B $5.6B $5.3B $5.6B $5.4B $5.2B $4.8B $4.5B
Goodwill $6.5B $4.7B $4.6B $4.3B $4.2B $4.2B $4.2B $4.0B $3.8B $3.3B
Intangible assets $14.0M $10.0M β€” β€” β€” β€” $2.0M $20.0M $15.0M $7.0M
Total assets $21.9B $17.5B $15.9B $15.6B $16.0B $15.2B $14.7B $14.5B $14.1B $13.2B
Total liabilities $19.7B $17.6B $16.8B $17.2B $17.1B $16.0B $15.4B $15.3B $15.4B $14.0B
Shareholders' equity $1.6B βˆ’$767M βˆ’$1.5B βˆ’$2.2B βˆ’$1.6B βˆ’$1.4B βˆ’$1.4B βˆ’$1.4B βˆ’$1.9B βˆ’$1.4B
Margins
Gross margin 83.7% 82.6% 83.4% 83.7% 83.3% 83.5% 83.8% 84.0% 84.6% 85.1%
Operating margin βˆ’4.7% βˆ’12.2% 1.5% 4.9% 9.6% 11.3% 6.7% 7.7% 4.3% 11.9%
EBITDA margin 1.3% βˆ’6.6% 6.4% 9.5% 14.3% 15.7% 11.1% 11.7% 8.1% 15.3%
Net margin βˆ’9.3% βˆ’16.0% βˆ’5.6% βˆ’5.1% 4.3% 1.9% 0.4% βˆ’1.1% βˆ’4.1% 4.1%
FCF margin 2.1% 1.4% βˆ’1.8% βˆ’0.4% 14.7% βˆ’4.9% βˆ’0.9% βˆ’2.1% 0.9% 1.7%
Returns
Return on capital βˆ’4.1% βˆ’11.8% 1.4% 4.7% 12.6% 10.1% 5.3% 6.2% 4.5% 15.9%
Return on capital employed βˆ’4.5% βˆ’12.4% 1.5% 4.9% 8.5% 10.9% 6.6% 7.8% 4.6% 13.5%
Return on equity βˆ’106.6% βˆ’580.0% β€” β€” β€” β€” β€” β€” β€” β€”
Return on assets βˆ’7.8% βˆ’12.5% βˆ’4.7% βˆ’4.3% 3.2% 1.5% 0.3% βˆ’0.9% βˆ’3.6% 3.7%
Growth
Revenue growth β€” βˆ’16.7% βˆ’7.8% βˆ’6.7% βˆ’10.8% 4.9% βˆ’1.3% 2.3% 1.2% βˆ’1.2%
Net income growth β€” β€” β€” β€” β€” βˆ’55.0% βˆ’80.0% βˆ’389.1% β€” β€”
EPS growth β€” β€” β€” β€” β€” βˆ’59.9% βˆ’80.1% βˆ’391.4% β€” β€”
FCF growth β€” βˆ’46.8% βˆ’221.1% β€” β€” βˆ’134.5% β€” β€” β€” 73.3%
Share count change β€” 0.9% 0.9% 0.9% 2.5% 12.1% βˆ’0.4% 0.3% 1.3% 2.2%
Financial health
Net debt / EBITDA 62.5x β€” 14.8x 10.6x 6.3x 6.1x 8.7x 8.0x 11.3x 5.4x
Debt / equity 9.4x β€” β€” β€” β€” β€” β€” β€” β€” β€”
Current ratio 1.6x 1.7x 1.5x 1.5x 1.6x 1.5x 1.4x 1.5x 1.4x 1.5x
Quick ratio 1.6x 1.7x 1.5x 1.5x 1.6x 1.5x 1.4x 1.5x 1.4x 1.5x
Capital allocation
Capex / revenue 4.0% 3.7% 3.7% 3.3% 3.7% 3.8% 3.4% 3.7% 2.8% 2.7%
Stock comp / revenue 0.2% 0.2% 0.1% 0.1% 0.1% 0.2% 0.2% 0.2% 0.1% 0.1%
Quality scores
Piotroski F-score β€” 4.0 5.0 5.0 6.0 3.0 7.0 5.0 4.0 8.0
Altman Z'' 0.3 βˆ’0.6 βˆ’0.3 βˆ’0.3 0.3 0.3 βˆ’0.1 0.0 βˆ’0.4 0.3
Accruals ratio βˆ’13.0% βˆ’16.4% βˆ’6.4% βˆ’6.7% βˆ’10.5% 2.3% βˆ’1.7% βˆ’2.4% βˆ’7.0% βˆ’0.2%

Source: SEC EDGAR XBRL filings (CIK 0001108109). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β€” not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move Β· ↡ to open